Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Crescent Biopharma (CBIO) EBITDA (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed EBITDA for 11 consecutive years, with -$92.4 million as the latest value for Q4 2025.

  • Quarterly EBITDA changed N/A to -$92.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$141.2 million through Dec 2025, changed N/A year-over-year, with the annual reading at -$153.9 million for FY2025, 761.6% down from the prior year.
  • EBITDA for Q4 2025 was -$92.4 million at Crescent Biopharma, down from -$24.6 million in the prior quarter.
  • The five-year high for EBITDA was -$2.4 million in Q1 2025, with the low at -$92.4 million in Q4 2025.
  • Average EBITDA over 5 years is -$16.6 million, with a median of -$11.1 million recorded in 2024.
  • Peak annual rise in EBITDA hit 78.42% in 2025, while the deepest fall reached 835.27% in 2025.
  • Over 5 years, EBITDA stood at -$17.4 million in 2021, then skyrocketed by 39.04% to -$10.6 million in 2022, then rose by 9.71% to -$9.6 million in 2023, then soared by 72.57% to -$2.6 million in 2024, then plummeted by 3411.86% to -$92.4 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$92.4 million, -$24.6 million, and -$21.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.